Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Mayzent

National Institute for Health and Care Excellence NICE logo

NICE backs two eye treatments

Novartis’ Lucentis and Alimera’s Iluvien received green light for NHS use

Biogen Idec building

Biogen Idec wins EU battle on Tecfidera exclusivity

Oral MS drug gains New Active Substance status

- PMLiVE

Sales down at Merck Serono on Rebif pressure

New MS drugs impact pharma company’s revenues

Novartis building

Novartis offloads diagnostics unit to Grifols for $1.7bn

Part of strategy to focus on more profitable businesses

- PMLiVE

Novartis debates future of Horsham site

UK research centre could close

Novartis building

Novartis weighs in on biosimilar naming debate

Files petition urging FDA to keep system where biosimilars share a name with the original drug

Biogen Idec building

Rocketing Tecfidera sales give Biogen Idec stellar Q3 results

Oral MS drug on course for blockbuster status in first year

- PMLiVE

Novartis’ Lucentis wins fourth NICE recommendation

But eye drug only recommended after a price-cutting patient access scheme offered

Novartis building

NICE backs Novartis/ ThromboGenics’ eye drug

Recommends Jetrea for NHS use in England and Wales to treat the rare disease vitreomacular traction

- PMLiVE

Novartis adds Facebook personalisation to sight campaign

Features the viewer's own pictures from the social network

Novartis building

Novartis’ omalizumab effective in chronic skin disease

Study backs extended use of asthma treatment Xolair

Novartis building

Novartis’ psoriasis drug set to challenge Amgen/Pfizer’s Enbrel

Secukinumab shows superior efficacy in phase III trial

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links